Literature DB >> 1234486

Plasma levels and beta-adrenoceptor blockade with acebutolol, practolol and propranolol in man.

M F Cuthbert, R F Collins.   

Abstract

1 The degree of beta-adrenoceptor blockade of isoprenaline-induced tachycardia has been determined in three healthy volunteers after the administration of single oral doses of acebutolol, practolol or propranolol. 2 Plasma levels of these drugs were determined either colorimetrically (acebutolol and practolol) or fluorimetrically (propranolol). The colorimetric assay of acebutolol in plasma is fully described but the other drugs were assayed by published methods. 3 The degree of beta-adrenoceptor blockade and the plasma level for acebutolol and practolol were well correlated, whereas in the case of propranolol correlation was poor, due in part to the presence in plasma of active metabolites not detected by the fluorimetric assay. The plasma levels of practolol and propranolol are in agreement with those previously reported. 4 The maximum cardiac beta-adrenoceptor blockade achieved in this study with the respective single oral doses of acebutolol (300 mg), practolol (400 mg) or propranolol (40 mg) were similar in each of the three subjects. Therefore the beta-adrenoceptor blocking potencies of these drugs against isoprenaline-induced tachycardia are inversely related to these doses; indicating that propranolol is 7-8 times more potent than acebutolol and the latter slightly more potent than practolol.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1234486      PMCID: PMC1402490          DOI: 10.1111/j.1365-2125.1975.tb00471.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Correlation of beta blockade with serum practolol levels after oral administration.

Authors:  D W Schneck; V S Aoki; F W Kroetz; W R Wilson
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

2.  Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate.

Authors:  S G Carruthers; J G Kelly; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

3.  Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise.

Authors:  I Brick; K J Hutchison; D G McDevitt; I C Roddie; R G Shanks
Journal:  Br J Pharmacol       Date:  1968-09       Impact factor: 8.739

4.  Pharmacokinetics of M&B 17,803A in animals and man.

Authors:  B Basil; R F Collins; M F Cuthbert
Journal:  Br J Pharmacol       Date:  1973-03       Impact factor: 8.739

5.  Effects of practolol on pressor responses to noxious stimuli in hypertensive patients.

Authors:  Y Traub; J A Shaver; R H McDonald; A P Shapiro
Journal:  Clin Pharmacol Ther       Date:  1973 Mar-Apr       Impact factor: 6.875

6.  Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man.

Authors:  D J Coltart; D G Shand
Journal:  Br Med J       Date:  1970-09-26

7.  Effect of M & B 17803A, a new -adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man.

Authors:  M F Cuthbert; K Owusu-Ankomah
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739

8.  Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol.

Authors:  J D Fitzgerald; S R O'Donnell
Journal:  Br J Pharmacol       Date:  1971-09       Impact factor: 8.739

9.  A comparison of the experimental anti-arrhythmic properties of acebutolol (M and B 17,803), propranolol and practolol.

Authors:  B Basil; R Jordan; A H Loveless; D R Maxwell
Journal:  Br J Pharmacol       Date:  1974-03       Impact factor: 8.739

10.  Beta-adrenoceptor blocking properties and cardioselectivity of M & B 17,803A.

Authors:  B Basil; R Jordan; A H Loveless; D R Maxwell
Journal:  Br J Pharmacol       Date:  1973-06       Impact factor: 8.739

View more
  20 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

2.  Comparative beta-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man.

Authors:  J F Giudicelli; C Richer; M Chauvin; N Idrissi; A Berdeaux
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

Review 3.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

4.  The effect of acebutolol on the cerebral circulation of man.

Authors:  P Hares; I M James; D Griffith
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

5.  Exercise responses of healthy subjects in the evaluation of cardioselectivity of beta-blockers.

Authors:  K L Woods; S P Linton; M J Kendall; E B Faragher; R J Grieve
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

6.  The effect of acebutolol on tachycardia and performance during competition rifle shooting.

Authors:  D O Gibbons; M Phillips
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

7.  Preliminary observations on the elimination of acebutolol in severe chronic renal failure.

Authors:  C M Kaye; J F Dufton
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

Review 8.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

9.  Comparative effects of acebutolol and practolol on the lipolytic response to isoprenaline.

Authors:  D O Gibbons; A F Lant; A Ashford; R F Collins; S Pinder
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

10.  Comparison of the effects of acebutolol (Sectral) and practolol (Eraldin) on airways obstruction in asthmatics.

Authors:  C Skinner; K N Palmer
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.